Notably, 50 μM metformin inhibited recombinant GPD2 and mitochondrial oxygen consumption in gluconeogenesis studies167; this dose was much lower than the concentrations required for metformin to exhibit in vitro anticancer activity or CI inhibition (≥1 mM184–186), as used in thyroid cancer studies. The gene discussed is GPD2; the disease is thyroid cancer.